The Effect of Calcifediol (Hy.D 25 SD/S) and Vitamin D3 on Muscle Strength in a Frail Elderly Population

NCT ID: NCT02349282

Last Updated: 2016-01-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In an ageing population, the need for interventions to help older people remain healthy, active and independent for as long as possible, increases. Although several studies suggest a beneficial effect of vitamin D3 on maintaining or improving muscle strength and physical functioning, particularly in vulnerable populations, results are contradicting. Randomized, placebo-controlled trials are needed to further establish the effect of vitamin D on muscle strength in the frail elderly population.The primary aim of this study is to determine the effect of daily supplementation with two different forms of vitamin D on muscle strength in frail elderly people over a period of 24 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Deficiency, Vitamin D Elderly, Frail

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Calcifediol 10 ug/day

Capsule with 10 ug/day Calcifediol taken together with breakfast for a total period of 24 weeks.

Group Type EXPERIMENTAL

Calcifediol 10ug/day

Intervention Type DIETARY_SUPPLEMENT

Vitamin D3 20 ug/day

Capsule with 20 ug/day Vitamin D3 taken together with breakfast for a total period of 24 weeks.

Group Type EXPERIMENTAL

Vitamin D3 20ug/day

Intervention Type DIETARY_SUPPLEMENT

Placebo

Capsule without active ingredients, taken together with breakfast for a total period of 24 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Calcifediol 10ug/day

Intervention Type DIETARY_SUPPLEMENT

Vitamin D3 20ug/day

Intervention Type DIETARY_SUPPLEMENT

Placebo

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hy.D Cholecalciferol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 25(OH)D levels 20-50 nmol/L.
* age 65 or older.
* physically frail (pre-frail or frail, based on the criteria designed by Fried et al.) (30). Frailty will be defined as a clinical syndrome in which one or more of the following criteria are present: unintentional weight loss (4.5 kg in past year), self-reported exhaustion (CES-D questionnaire), weakness (grip strength), slow walking speed and low physical activity (Minnesota questionnaire). More details on these criteria are described in chapter 6.3.2.
* body mass index between 18.5 and 35 kg/m2.
* willingness and ability to comply with the protocol, including performance of the knee extension strength test.

Exclusion Criteria

* Medical Illness:

* malabsorption syndrome: known intestinal malabsorption, celiac diseases, inflammatory bowel disease;
* diseases that may enhance serum calcium concentration: sarcoidosis, lymphoma, kidney stone in the last 10 years, primary hyperparathyroidism;
* abnormal indices of calcium metabolism, uncontrolled hypocalcaemia;
* diagnosed renal insufficiency;
* diagnosed cancer; currently diagnosed or undergoing treatment.
* Hypercalcemia: serum calcium adjusted for albumin of \> 2.6 nmol/L.
* Medication: interfering with vitamin D metabolism and vitamin D supplementation (bisphosphonate, PTH treatment, tuberculostatica, anti-epileptica).
* Subject not able (when medically necessary/ advised) or not willing to stop the use of vitamin D containing supplements during the study.
* (Expected) increase in exposure to sunlight (e.g. travelling to a sunny resort) during intervention period.
* Patient heavily consumes alcohol containing products defined as greater than \> 21 drinks of alcoholic beverages per week.
* Planned surgery which can affect study measures (taking into account duration of hospitalisation and recovery).
* Participation in another clinical trial.
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Top Institute Food and Nutrition

OTHER

Sponsor Role collaborator

DSM Nutritional Products, Inc.

INDUSTRY

Sponsor Role collaborator

Wageningen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wageningen University

Wageningen, Gelderland, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Hangelbroek RWJ, Vaes AMM, Boekschoten MV, Verdijk LB, Hooiveld GJEJ, van Loon LJC, de Groot LCPGM, Kersten S. No effect of 25-hydroxyvitamin D supplementation on the skeletal muscle transcriptome in vitamin D deficient frail older adults. BMC Geriatr. 2019 May 28;19(1):151. doi: 10.1186/s12877-019-1156-5.

Reference Type DERIVED
PMID: 31138136 (View on PubMed)

Vaes AMM, Tieland M, Toussaint N, Nilwik R, Verdijk LB, van Loon LJC, de Groot LCPGM. Cholecalciferol or 25-Hydroxycholecalciferol Supplementation Does Not Affect Muscle Strength and Physical Performance in Prefrail and Frail Older Adults. J Nutr. 2018 May 1;148(5):712-720. doi: 10.1093/jn/nxy024.

Reference Type DERIVED
PMID: 30053278 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL48127.081.148

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Vitamin D Treatment on Fatigue
NCT02022475 COMPLETED PHASE3
High-dose Vitamin D Supplements in Older Adults
NCT03613116 ACTIVE_NOT_RECRUITING PHASE2